Inspire Medical Systems (INSP) Expected to Release Earnings on Monday

Key Points

• Inspire Medical Systems is expected to report Q3 2026 results after Monday’s market close. Analysts anticipate EPS of $0.087 and revenue of $204.31 million, while the company’s FY 2026 EPS guidance is $1.05–$1.45.
• The company’s latest quarterly results exceeded expectations, with EPS of $0.14 versus a consensus loss estimate of $0.24 and revenue of $200.58 million versus $194.72 million expected. However, revenue declined 7.6% year over year.
• Analyst sentiment remains mixed: the stock has an overall “Hold” rating and a consensus price target of $68.82, despite recent target increases and a current share price of $71.09.

Inspire Medical Systems (NYSE:INSP - Get Free Report) is expected to release its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Inspire Medical Systems to post earnings of $0.0870 per share and revenue of $204.31 million for the quarter. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Investors are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The company had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the previous year, the business earned $0.45 EPS. Inspire Medical Systems's revenue was down 7.6% compared to the same quarter last year. On average, analysts expect Inspire Medical Systems to post $1.24 EPS for the current fiscal year and $1.54 EPS for the next fiscal year.

Inspire Medical Systems Stock Down 0.0%

Shares of INSP stock opened at $71.09 on Monday. The stock has a fifty day moving average of $67.54 and a 200 day moving average of $55.44. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of 15.39, a PEG ratio of 5.38 and a beta of 0.73.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Piper Sandler increased their price target on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 4th. Zacks Research downgraded Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 22nd. Royal Bank Of Canada raised their price target on Inspire Medical Systems from $60.00 to $75.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 1st. Finally, Oppenheimer upgraded Inspire Medical Systems from a "market perform" rating to an "outperform" rating and set a $85.00 price target for the company in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $68.82.

Insider Transactions at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 2.20% of the stock is owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.